Page 165 - CW E-Magazine (2-7-2024)

News from Abroad

manufacturing and control (CMC) analy device testing, cell and gene therapy, testing to its GMP portfolio of services
tical capabilities as part of its clinical protein characterisation and mass spec- at the Middleton facility. With the
development and laboratory services. trometry analysis for all phases of drug addition of this capability, as well as the
development. The latest addition to addition of the new building, the site
“As research in biopharmaceutical the GMP campus provides a multi-use offers a full complement of end-to-end
therapies continues to rapidly expand, and flexible biosafety level 2 laboratory laboratory services.
we are excited to expand our overall that includes a purpose-built liquid
capacity and capabilities in laboratory chromatography-mass spectrometry In addition to GMP and bioanalyti-
services to help our customers deliver and protein characterisation space, two cal labs in Middleton, Thermo Fisher’s
therapies that meet the highest quality large molecular suites with access con- clinical research laboratory business
and safety standards for patients,” said trolled pre- and post-amplification labs, includes bioanalytical, biomarker and
Mr. Leon Wyszkowski, President, analy- and two large general-use labs. The vaccine sciences labs in Richmond,
tical services, clinical research, Thermo- expansion will add up to 350 scientists Virginia; a GMP lab in Athlone,
Fisher Scientific. and laboratory support professionals to Ireland; central labs and biomarker oper-
the almost 2,300 employees working ations in Brussels, Belgium, Highland
The GMP site offers high-quality across the research campus. Heights, Kentucky, and Singapore;
analytical services for small molecules and bioanalytical, biomarker, vaccine
and biologics, including biopharma- Earlier this year, Thermo Fisher sciences and central labs in Suzhou,
ceuticals, inhaled pharmaceuticals and announced the addition of biosafety China.
AI ASSISTANCE
Syensqo looks to enhance employee productivity

with new internal Chatbot

Syensqo, previously part of Belgium’s
Solvay group, is leveraging artificial
intelligence (AI) with the launch of
‘SyGPT’, a secure internal version of
ChatGPT, that promises to raise work-
place efficiency and boost innovation.

‘SyGPT’, which was designed
with Microsoft and is currently based
on ‘GPT-4 Turbo’, offers a robust and
secure solution, tailored to meet the
needs of Syensqo employees. Unlike
public chatbots, ‘SyGPT’ ensures com-
plete confidentiality, allowing users
to handle sensitive information with-
out compromising security. ‘SyGPT’ ciples has driven our agile development frequently upgrade SyGPT to enable
serves as a versatile personal assistant approach, ensuring rapid delivery and more tailored and insightful inter-
for day-to-day activities or scientific continuous improvement. SyGPT is actions, transforming the way employees
research tasks and aims to free up several designed by our employees to enhance access and utilise company knowledge.
hours each week for employees, as per their performance and we are excited AI will also be further developed to
Syensqo. about the journey ahead and the endless upgrade and enhance the efficiency
possibilities that SyGPT and AI will of all of the company’s processes and
The Syensqo.ai team worked over offer our company,” said Mr. Vincent Syensqo.ai is engaging in other projects
the past three months to develop this Colegrave, Head of the Syensqo.ai team. to propel the company forward, notably
tool. “Our focus on business needs, relating to its customer service and
cybersecurity and responsible AI prin- Looking ahead, Syensqo.ai plans to innovation capabilities.

Chemical Weekly July 2, 2024 165

Contents Index to Advertisers Index to Products Advertised